Dr. Glode is the medical oncology specialist for prostate and genitourinary (GU) cancers at Shaw Regional Cancer Center. He was the principal investigator on the study leading to the approval of leuprolide, an injection used for treating prostate cancer. He was also on the only nation-wide National Cancer Institute sponsored adjuvant treatment protocol for high risk prostate cancer patients following surgery. With a longstanding interest in GU oncology, Dr. Glode's laboratory interests include studies on a toxin-conjugate that appears capable of directly killing tumor cells aberrantly expressing the GnRH receptor and eliminating pituitary gonadotropes. He also has pursued additional funded research evaluating the efficacy of a flavanone found in milk thistle. This interesting polyphenol has significant anti-tumor activity in animal models and no apparent toxicity. An ongoing study is evaluating the human tolerance, and lab studies continue to look at its efficacy as a bladder cancer prevention agent and enhancer of chemotherapeutic agents.
Dr. Glode is a Fellow of the American Society of Clinical Oncology and the American College of Physicians. He has been the principle investigator on numerous basic science and clinical research grants and has been recognized by the American Association of Cancer Research for his efforts in organizing a course called "Molecular Biology for Clinical Oncologists." He is a scientific advisor to several pharmaceutical companies, a member of the External Advisory Board for the Department of Defense Prostate Cancer Research Program, and he has started three biotechnology companies. He has published more than 150 scientific articles, book chapters and monographs, and he is the Medical Director of the GU Oncology Program at the University of Colorado Cancer Center.